
Luis V Syro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9170469/publications.pdf Version: 2024-02-01



Luis V Sypo

#	Article	IF	CITATIONS
1	Clinical Biology of the Pituitary Adenoma. Endocrine Reviews, 2022, 43, 1003-1037.	8.9	81
2	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
3	Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection. Pituitary, 2021, 24, 839-853.	1.6	24
4	Overproduction of Hormones by Pituitary Tumors. , 2020, , 655-665.		1
5	Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective. Pituitary, 2020, 23, 327-337.	1.6	49
6	Pituitary pathology in traumatic brain injury: a review. Pituitary, 2019, 22, 201-211.	1.6	36
7	Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society―survey. Pituitary, 2019, 22, 37-45.	1.6	24
8	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	1.9	196
9	DICER1 gene mutations in endocrine tumors. Endocrine-Related Cancer, 2018, 25, R197-R208.	1.6	29
10	65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update. Endocrine-Related Cancer, 2018, 25, T159-T169.	1.6	18
11	Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. Frontiers in Endocrinology, 2018, 9, 318.	1.5	47
12	Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas: a Histologic Study. Pathology and Oncology Research, 2017, 23, 803-809.	0.9	6
13	Immunoglobulin G4 (IgG4)-Related Hypophysitis. Endocrine Pathology, 2017, 28, 308-314.	5.2	8
14	From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocrine-Related Cancer, 2017, 24, C5-C8.	1.6	262
15	Nonpituitary Sellar Masses. , 2017, , 631-641.		3
16	Selective molecular biomarkers to predict biologic behavior in pituitary tumors. Expert Review of Endocrinology and Metabolism, 2017, 12, 177-185.	1.2	8
17	Alpha subunit in clinically non-functioning pituitary adenomas: An immunohistochemical study. Pathology Research and Practice, 2017, 213, 1130-1133.	1.0	3
18	Pathology of CH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary, 2017, 20, 84-92.	1.6	34

#	Article	IF	CITATIONS
19	Clinicopathologic features of familial pituitary adenomas. Diagnostic Histopathology, 2016, 22, 85-91.	0.2	4
20	Biomarkers of pituitary carcinomas. Expert Review of Endocrinology and Metabolism, 2016, 11, 253-261.	1.2	2
21	Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. Pituitary, 2016, 19, 345-355.	1.6	72
22	Crooke's Cell Tumors of the Pituitary. Neurosurgery, 2015, 76, 616-622.	0.6	38
23	Human Kallikrein 10 Expression in Surgically Removed Human Pituitary Corticotroph Adenomas. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 433-437.	0.6	5
24	Progress in the Diagnosis and Classification of Pituitary Adenomas. Frontiers in Endocrinology, 2015, 6, 97.	1.5	51
25	Invasive, Atypical and Aggressive Pituitary Adenomas and Carcinomas. Endocrinology and Metabolism Clinics of North America, 2015, 44, 99-104.	1.2	59
26	Treatment of Invasive Silent Somatotroph Pituitary Adenoma with Temozolomide. Report of a Case and Review of the Literature. Endocrine Pathology, 2015, 26, 135-139.	5.2	7
27	Letter to the Editor. Endocrine Pathology, 2015, 26, 93-94.	5.2	13
28	Autophagy in endocrine tumors. Endocrine-Related Cancer, 2015, 22, R205-R218.	1.6	31
29	Current status on histological classification in Cushing's disease. Pituitary, 2015, 18, 217-224.	1.6	19
30	Biomarkers of acromegaly. Endocrine, 2015, 49, 4-5.	1.1	1
31	Human kallikrein 10 in surgically removed human pituitary adenomas. Hormones, 2014, 14, 272-9.	0.9	3
32	Autophagy in the endocrine glands. Journal of Molecular Endocrinology, 2014, 52, R151-R163.	1.1	76
33	Improving differential diagnosis of pituitary adenomas. Expert Review of Endocrinology and Metabolism, 2014, 9, 377-386.	1.2	9
34	Aggressive pituitary adenomas—diagnosis and emerging treatments. Nature Reviews Endocrinology, 2014, 10, 423-435.	4.3	239
35	Melanoma of the sellar region mimicking pituitary adenoma. Neuropathology, 2013, 33, 175-178.	0.7	13
36	Stem Cells and Cancer Stem-Like Cells in Endocrine Tissues. Endocrine Pathology, 2013, 24, 1-10.	5.2	31

#	Article	IF	CITATIONS
37	Pituitary stem cells: candidates and implications. Pituitary, 2013, 16, 413-418.	1.6	7
38	Microvessel density and VEGF expression in pituitaries of pregnant women. Hormones, 2013, 12, 292-297.	0.9	2
39	Ghrelin: A GH-Releasing, Appetite-Regulating Gastric Hormone. Advances in Neuroimmune Biology, 2013, 4, 51-65.	0.7	0
40	Autophagy in pituitary tumors. FASEB Journal, 2013, 27, 1086.6.	0.2	0
41	Neurocysticercosis, Meningioma, and Silent Corticotroph Pituitary Adenoma in a 61-Year-Old Woman. Case Reports in Pathology, 2012, 2012, 1-5.	0.2	6
42	Ghrelin Immunoexpression in the Human Hypophysis. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 77-81.	0.6	5
43	O-6-Methylguanine-DNA Methyltransferase (MGMT) Immunohistochemical Expression in Pituitary Corticotroph Adenomas. Neurosurgery, 2012, 70, 491-496.	0.6	33
44	Non-uniform Response to Temozolomide Therapy in a Pituitary Gonadotroph Adenoma. Canadian Journal of Neurological Sciences, 2012, 39, 683-685.	0.3	9
45	Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. Pituitary, 2012, 15, 342-349.	1.6	10
46	Anti-VEGF therapy in pituitary carcinoma. Pituitary, 2012, 15, 445-449.	1.6	115
47	Pituitary immunoexpression of ghrelin in anorexia nervosa. Pituitary, 2012, 15, 533-538.	1.6	3
48	Prolactinomas: diagnosis and treatment. Expert Review of Endocrinology and Metabolism, 2012, 7, 233-241.	1.2	5
49	Necrotizing Infundibuloneurohypophysitis: Case Report and Literature Review. Endocrine Pathology, 2012, 23, 205-211.	5.2	5
50	Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics, 2012, 67, 119-123.	0.6	42
51	Pituitary tumors in patients with MEN1 syndrome. Clinics, 2012, 67, 43-48.	0.6	37
52	Tumefactive Postmenopausal Gonadotroph Cell Hyperplasia. Endocrine Pathology, 2012, 23, 108-111.	5.2	4
53	Treatment of Aggressive Pituitary Adenomas and Carcinomas – An Overview. European Neurological Review, 2012, 7, 178.	0.5	0
54	Treatment of Aggressive Pituitary Adenomas and Carcinomas—An Overview. US Endocrinology, 2012, 08, 50.	0.3	0

#	Article	IF	CITATIONS
55	VEGF immunoexpression in the pituitaries of pregnant women. FASEB Journal, 2012, 26, 48.1.	0.2	0
56	Increased microvessel density in the pituitarires of pregnant women. FASEB Journal, 2012, 26, 832.12.	0.2	0
57	Biomarkers of pituitary neoplasms. Anticancer Research, 2012, 32, 4639-54.	0.5	38
58	Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy. Hormones, 2011, 10, 162-167.	0.9	45
59	Ghrelin immunoexpression in pituitary adenomas. Pituitary, 2011, 14, 318-322.	1.6	12
60	Necrotizing Granulomatous Hypophysitis Presenting as a Sellar Mass. Endocrine Pathology, 2011, 22, 6-9.	5.2	10
61	Undifferentiated Sarcoma of the Sellar Region. Endocrine Pathology, 2011, 22, 159-164.	5.2	5
62	MicroRNAs in the Human Pituitary. Endocrine Pathology, 2011, 22, 134-143.	5.2	48
63	Treatment of pituitary neoplasms with temozolomide. Cancer, 2011, 117, 454-462.	2.0	94
64	Reply to treatment of pituitary neoplasms with temozolomide. Cancer, 2011, 117, 4102-4102.	2.0	1
65	Ghrelin Immunexpression in Pituitary Adenomas. FASEB Journal, 2011, 25, 1001.13.	0.2	0
66	Immunohistochemical Demonstration of Ghrelin in the Nontumorous Human Hypophysis. FASEB Journal, 2011, 25, 1002.5.	0.2	0
67	Low Immunohistochemical Expression of MGMT in ACTH Secreting Pituitary Tumors of Patients with Nelson Syndrome. Endocrine Pathology, 2010, 21, 227-229.	5.2	18
68	MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary, 2010, 13, 367-379.	1.6	51
69	Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones, 2009, 8, 303-306.	0.9	24
70	Pituitary Adenoma with Peliosis: A Report of Two Cases. Endocrine Pathology, 2009, 20, 41-45.	5.2	6
71	Collision Tumors of the Sella: Craniopharyngioma and Silent Pituitary Adenoma Subtype 3: Case Report. Endocrine Pathology, 2009, 20, 50-55.	5.2	25
72	Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Research, 2009, 29, 3759-68.	0.5	101

#	Article	IF	CITATIONS
73	MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathologica, 2008, 115, 261-262.	3.9	100
74	Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Human Pathology, 2007, 38, 185-189.	1.1	96
75	Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clinical Endocrinology, 2006, 65, 552-553.	1.2	90
76	Plurihormonality in Pituitary Adenomas Associated with Acromegaly. Endocrine Pathology, 2006, 17, 291-296.	5.2	13
77	Inflammatory pseudotumor of the pituitary: Case report. World Neurosurgery, 2004, 62, 264-267.	1.3	12
78	Prolactin-Producing Pituitary Adenoma Associated with Prolactin Cell Hyperplasia. Endocrine Pathology, 2002, 13, 157-166.	5.2	8